A network meta‐analysis was performed to indirectly consider the efficacy and safety of PD‐1/PD‐L1 inhibitors, and the Markov model was established to compare their economic.The efficacy and safety of the four PD‐1/PD‐L1 inhibitors analyzed in this study are similar.From the perspective of the Chinese healthcare system, nivolumab therapy is a cost‐effective alternative to other drugs as first‐line treatments for advanced NSCLC with high‐level PD‐L1 expression. This evidence concerns the gene CD274 and non-small cell lung carcinoma.